- The generic drug market is seeing significant growth, driven by Indian firms and regional markets, with major players like Aurobindo, J&J, and GSK involved.
- Indian drug makers are targeting the North American market.
India supplies 40 per cent of generic drugs consumed in the US, with government programs like Medicare procuring these drugs to cut expenditure, though tariff hikes pose a threat.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
India supplies 40 per cent of generic drugs consumed in the US, with government programs like Medicare procuring these drugs to cut expenditure, though tariff hikes pose a threat.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Slotkin argues Medicare should negotiate drug prices while criticizing Trump's proposed tariffs on generic drugs.Sub-event
Indian generics supply 40% of US consumption, but tariff hikes threaten market share.1 source
Keep exploring
The entities involved
-
Medicare
US federal health insurance
Related events
Coverage
Newest first; wire copies grouped- aninews.in"Cost will go up for US": USISPF Chief warns against proposed tariffs on Indian generic drugs